SynthesisMedical oncology (Northwood, London, England)2024
A comprehensive review of phytoconstituents in liver cancer prevention and treatment: targeting insights into molecular signaling pathways.
Synthesis in Medical oncology (Northwood, London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Ultrasound-assisted cocrystal of emodin and matrine: An opportunity to improve synergistic bioavailability.Ultrasonics sonochemistry · 2026Article
- Therapeutic Insights into the Hepatoprotective Effect of Strobilanthes callosa.Cell biochemistry and biophysics · 2026Article
- Mitochondrial-Based Nanomedicine in Treatment of Liver Cancer.Molecular biotechnology · 2026Review
- Herbal remedies for hepatic diseases: A review of medicinal herbs in the treatment of liver disorders.Chinese herbal medicines · 2026Review
- Hinokitiol as a Promising Anticancer Agent: Mechanisms of Action, Potential in Combination Therapy, and Overcoming Chemoresistance.Current pharmaceutical design · 2026Review
- Epigenetic Alterations in Hepatocellular Carcinoma: Mechanisms, Biomarkers, and Therapeutic Implications.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Antitumor Alkaloids in Tibetan Corydalis: Chemical Diversity and Pharmacological Insights.Medical science monitor : international medical journal of experimental and clinical research · 2025Review
- Unveiling the anticancer potential of Pinostrobin: mechanisms of action, pharmacokinetic insights, and therapeutic prospects.Medical oncology (Northwood, London, England) · 2025Review
- Liquid Biopsy for Medical Imaging Analysis in Cancer Diagnosis.Current pharmaceutical design · 2025Review
- LncRNA HAGLROS: A Vital Oncogenic Propellant in Various Human Cancers.Current drug targets · 2025Review
- Oxidative stress and senescence in aging kidneys: the protective role of SIRT1.EXCLI journal · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary liver cancer is a type of cancer that develops in the liver. Hepatocellular carcinoma is a primary liver cancer that usually affects adults. Liver cancer is a fatal global condition that affects millions of people worldwide. Despite advances in technology, the mortality rate remains alarming. There is growing interest in researching alternative medicines to prevent or reduce the effects of liver cancer. Recent studies have shown growing interest in herbal products, nutraceuticals, and Chinese medicines as potential treatments for liver cancer. These substances contain unique bioactive compounds with anticancer properties. The causes of liver cancer and potential treatments are discussed in this review. This study reviews natural compounds, such as curcumin, resveratrol, green tea catechins, grape seed extracts, vitamin D, and selenium. Preclinical and clinical studies have shown that these medications reduce the risk of liver cancer through their antiviral, anti-inflammatory, antioxidant, anti-angiogenic, and antimetastatic properties. This article discusses the therapeutic properties of natural products, nutraceuticals, and Chinese compounds for the prevention and treatment of liver cancer.
Indexed as
Identifiers
38703282What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.